Compass Therapeutics' (CMPX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research note issued to investors on Monday,Benzinga reports. The firm currently has a $32.00 price target on the stock.

CMPX has been the subject of several other reports. Leerink Partnrs raised Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Leerink Partners raised shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Piper Sandler assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Finally, Wedbush reissued an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 1st. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $13.38.

Compass Therapeutics Price Performance

Shares of CMPX stock traded up $0.07 on Monday, hitting $1.89. The stock had a trading volume of 732,940 shares, compared to its average volume of 882,670. The business has a 50 day moving average of $2.10 and a 200 day moving average of $2.10. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08. The stock has a market cap of $261.35 million, a price-to-earnings ratio of -5.11 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, research analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock in a transaction on Monday, April 7th. The shares were purchased at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now owns 21,000 shares of the company's stock, valued at approximately $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Insiders own 28.50% of the company's stock.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. MPM Bioimpact LLC grew its position in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after buying an additional 2,926,002 shares during the period. Enavate Sciences GP LLC purchased a new stake in Compass Therapeutics in the fourth quarter worth about $11,293,000. Tang Capital Management LLC increased its stake in shares of Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. Rock Springs Capital Management LP lifted its holdings in shares of Compass Therapeutics by 2.7% during the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock valued at $8,380,000 after purchasing an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP boosted its position in shares of Compass Therapeutics by 2.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock worth $4,284,000 after purchasing an additional 75,000 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.